The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study

• Published in: Cancer management and research Vol. 13; pp. 6123 - 6128
• Main Authors: Wang, Yu-Xin, Li, Feng-Lian, Du, Li-Xin, Liu, Jun-Fang, Huo, Li-Gang, Li, Shu-Qing, Tian, Bin
• Format: Journal Article
• Language: English
• Published: Macclesfield Dove Medical Press Limited 01.01.2021; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Antigens; Breast cancer; Cancer; cancer/testis antigens; co-expression; Epidermal growth factor; Esophageal cancer; Estrogen; Estrogens; Ethylenediaminetetraacetic acid; Immunotherapy; mage-a; Medical prognosis; Melanoma; Metastasis; ny-eso-1; Oncology, Experimental; Original Research; Prognosis; Proteins; Squamous cell carcinoma; Survival analysis; Tumor proteins; Vascular endothelial growth factor; New York; United States > US
• ISSN: 1179-1322; 1179-1322
• DOI: 10.2147/CMAR.S316759

Objective: The aim of this study was to quantify the expression of melanoma-antigen family A proteins (MAGE-A) and New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in breast cancer and establish the prognosis of breast cancer patients with MAGE-A and NY-ESO-1 co-expression. Methods: A total of 122 patients with breast cancer were recruited for this study. Their clinicopathological data were collected retrospectively, and the MAGE-A and NY-ESO-1 expressions in paraffin-embedded specimens from the 122 patients were evaluated using immunohistochemical analysis. In addition, the survival states of the patients were recorded. Results: Fifty-four patients (44.26%) were MAGE-A positive and 46 (37.70%) were NY-ESO-1 positive. Interestingly, 22 of the 46 NY-ESO-1-positive cases co-expressed MAGE-A. The expression of MAGE-A was positively associated with estrogen-receptor status ([chi square] = 4.026, p = 0.045) and human epidermal growth factor receptor 2 status ([chi square] = 5.482, p = 0.019), while the expression of NY-ESO-1 was positively associated with p53 expression ([chi square] = 4.541, p = 0.033). Of the 122 patients, the lowest survival rate was observed in patients with NY-ESO-1 (+)/MAGE-A (+), with a 5-year survival rate of 59.09% and a median survival of 97 months. Conclusion: The results showed that MAGE-A and NY-ESO-1 were frequently expressed in breast cancer patients. The co-expression of MAGE-A and NY-ESO-1 occurred in about 18% of these patients, and it may indicate a poor prognosis. Keywords: breast cancer, cancer/testis antigens, MAGE-A, NY-ESO-1, co-expression